Ketogenic Diet in Rheumatoid Arthritis (RA)
Launched by UNIVERSITY OF OKLAHOMA · Mar 23, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of RA according to the ACR/EULAR 2010 criteria for RA.
- • On stable doses of DMARDs and/ or biological agents (≥ 2 months prior to study enrollment)
- Exclusion Criteria:
- • Chronic inflammatory/ autoimmune disease other than RA (e.g. gout, inflammatory bowel disease such as Crohn's disease or ulcerative colitis, lupus, myositis, etc.)
- • Prednisone or other glucocorticoid use in the last 4 weeks (exception: intra-articular glucocorticoid injections)
- • Insulin use
- • Hospitalization in the 30 days prior to study enrollment
- • Acute or uncontrolled disease (e.g. cirrhosis, COPD, CKD)
- • Malignancy
- • Chronic infection (HIV, hep B/C, etc.)
- • Heavy drinking
- • On a ketogenic diet or exogenous ketone supplement (lses than 3 months prior to study enrollment)
- • Recent weight loss (\>5% in the last 2 months)
About University Of Oklahoma
The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Oklahoma City, Oklahoma, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials